PE20241385A1 - Formulaciones de radiprodil - Google Patents

Formulaciones de radiprodil

Info

Publication number
PE20241385A1
PE20241385A1 PE2024000212A PE2024000212A PE20241385A1 PE 20241385 A1 PE20241385 A1 PE 20241385A1 PE 2024000212 A PE2024000212 A PE 2024000212A PE 2024000212 A PE2024000212 A PE 2024000212A PE 20241385 A1 PE20241385 A1 PE 20241385A1
Authority
PE
Peru
Prior art keywords
radiprodil
formulations
compound
formula
pharmaceutically acceptable
Prior art date
Application number
PE2024000212A
Other languages
English (en)
Spanish (es)
Inventor
Marie Genin
Pierandrea Muglia
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of PE20241385A1 publication Critical patent/PE20241385A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2024000212A 2021-08-06 2022-08-05 Formulaciones de radiprodil PE20241385A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (1)

Publication Number Publication Date
PE20241385A1 true PE20241385A1 (es) 2024-07-09

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000212A PE20241385A1 (es) 2021-08-06 2022-08-05 Formulaciones de radiprodil

Country Status (12)

Country Link
US (2) US20250127770A1 (https=)
EP (1) EP4380547A1 (https=)
JP (1) JP2024529185A (https=)
KR (1) KR20240052765A (https=)
CN (1) CN118019521A (https=)
AU (1) AU2022323381A1 (https=)
CA (1) CA3228004A1 (https=)
CO (1) CO2024002715A2 (https=)
IL (1) IL310652A (https=)
MX (1) MX2024001744A (https=)
PE (1) PE20241385A1 (https=)
WO (1) WO2023014956A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137652A2 (en) * 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
HUP0900130A3 (en) * 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Also Published As

Publication number Publication date
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
US20250127770A1 (en) 2025-04-24
WO2023014956A1 (en) 2023-02-09
AU2022323381A1 (en) 2024-03-21
JP2024529185A (ja) 2024-08-01
KR20240052765A (ko) 2024-04-23
EP4380547A1 (en) 2024-06-12
US20260053786A1 (en) 2026-02-26
CA3228004A1 (en) 2023-02-09
WO2023014956A9 (en) 2023-12-14
CN118019521A (zh) 2024-05-10
MX2024001744A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
ECSP078023A (es) Ingrediente farmacéutico activo en base a canabinoide
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
ECSP12011958A (es) Composiciones farmacéuticas que comprenden ligandos de receptores sigma
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
MX2024014628A (es) Compuesto para inhibir o degradar bcl6 y uso de este en farmacia
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
AR074309A1 (es) Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
PE20241385A1 (es) Formulaciones de radiprodil
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR133241A1 (es) Compuestos, composiciones y métodos
CL2021001621A1 (es) Formulaciones orales de branaplam
CO2024009774A2 (es) Composiciones que contienen fexofenadina
MX2022002022A (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones.
AR132166A1 (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
AR131625A1 (es) Compuestos, composiciones y métodos de uso para tratar el hipoparatiroidismo y la osteoporosis
ECSP099733A (es) Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias